Navigant Acquires Dymedex Consulting to Expand Its Life Sciences Practice and Overall Capabilities in Medical Technology

CHICAGO–(BUSINESS WIRE)–September 1, 2016

Navigant (NCI) today announced it acquired Dymedex Consulting, LLC, a Minnesota-based firm that provides data-driven market analysis to accelerate adoption and maximize growth for medical device companies. Dymedex offers insights through global strategic market assessments, tactical geography planning, and market landscape analysis.

The addition of the experienced Dymedex team, as well as the firm’s proprietary market development tools and methodologies, expands Navigant’s capabilities in the medical technology and life sciences industries. Navigant also plans to make the Dymedex tools, methodologies and expertise available to its healthcare clients.

“In today’s medical device market, it is critical that companies create the conditions necessary to optimize growth, utilization, and adoption. Dymedex has a proven methodology to assist companies in accelerating the development of global markets,” said Eduardo Schur, managing director and Global Life Sciences practice leader, Navigant. “And while Dymedex has been successful in the medical technology field, we are excited by the opportunity to expand their methodologies into other life sciences areas such as pharmaceuticals and biotech.”

The Dymedex team, including founders Joseph Galatowitsch and Ross Meisner, will join the Navigant Life Sciences practice within the company’s Healthcare segment.

“Uncovering critical market insights and facilitating data-driven decisions is vital to the success of life science and med tech companies,” said Joseph Galatowitsch, co-founder of Dymedex Consulting and managing director at Navigant. “The combination of Dymedex’s proprietary tools and methodologies with Navigant’s deep industry expertise and global footprint will enable our clients to fully capitalize on their opportunities.”

Based in Minneapolis, Dymedex has evaluated over 100 different medical technologies for their clients and worked in nearly 20 countries around the world. With deep knowledge of the challenges clients face, Dymedex helps clients address complex problems across multiple therapeutic and clinical areas and works on a wide range of medical technologies and business models, including monitoring and diagnostic products, therapies of all types, surgical tools, disposables, capital equipment, and other complex or combination devices.

About Navigant

Navigant Consulting, Inc. (NCI) is a specialized, global professional services firm that helps clients take control of their future. Navigant’s professionals apply deep industry knowledge, substantive technical expertise, and an enterprising approach to help clients build, manage and/or protect their business interests. With a focus on markets and clients facing transformational change and significant regulatory or legal pressures, the Firm primarily serves clients in the healthcare, energy and financial services industries. Across a range of advisory, consulting, outsourcing, and technology/analytics services, Navigant’s practitioners bring sharp insight that pinpoints opportunities and delivers powerful results. More information about Navigant can be found at navigant.com.

About Dymedex

Dymedex is a market development consulting firm that helps medical technology companies reach full market potential by using data-driven market analysis and insight to improve decision-making. Dymedex has developed over 100 customized medical technology market development plans in all major markets globally. Dymedex understands the industry’s challenges, and relies on more than 80 years of combined experience that includes nearly every major disease and condition. Data-driven critical thinking, shaped by broad experience, helps us consistently deliver key insights. At Dymedex, we are driven to provide foundational scientific market analysis that organizations can rely on to move forward with confidence.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005264/en/